Clinical Trials Browser

NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Phase 3 Recruiting

600 enrolled

Lymphoid

Classic Follicular Lymphoma

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Active not recruiting

422 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Phase 3 Active not recruiting

689 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

35 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Phase 1 Active not recruiting

4 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

3 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04626791 2024-03-12

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT03864419 2024-01-03

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Phase 1 Terminated

18 enrolled

Lymphoid

Multi-centric Castleman's Disease, Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse